TopFunds

Moderna

NASDAQ: MRNA

Stock price

197 USD

(+0%) TODAY

Biotechnology
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
(3.8)
(0.7)
(1.2)
(1.5)
(2)
28.3
20.1
(12.3)
(9.3)
(7.3)
7.5%
02Free cash flow per share
0.5
(1)
(1.3)
(1.5)
5.1
30.9
11
(10)
(10.6)
(5.3)
-
03Dividends per share
-
-
-
-
-
-
-
-
-
-
-
04Dividends payout, %
(0.3)%
(0.6)%
-
-
-
-
-
-
-
-
97.9%
PROFIT AND LOSS STATEMENT
05Revenue
108.4
205.8
135.1
60.2
803.4
17,736
18,875
6,848
3,199
1,944
37.8%
06% Change
-
-
-
-
-
-
-
-
-
-
37.8%
07Cost of revenue
(15.1)
(20.5)
(24.9)
(31)
(39.2)
(2,617)
(5,416)
(4,693)
(1,464)
(868)
56.8%
08Gross profit
93.3
185.3
110.2
29.2
764.2
15,119
13,459
2,155
1,735
1,076
31.2%
09% Margin
86.1%
90%
81.6%
48.5%
95.1%
85.2%
71.3%
31.5%
54.2%
55.4%
69.9% A
10Operating expenses
(317.1)
(454.6)
(94.3)
(574.9)
(1,527)
(1,823)
(4,039)
(6,394)
(5,680)
(4,150)
33.1%
11% of Revenue
(292.5)%
(220.9)%
(69.8)%
(954.9)%
(190.1)%
(10.3)%
(21.4)%
(93.4)%
(177.6)%
(213.5)%
(224.4)% A
12Operating Income
(223.8)
(269.4)
(468.9)
(545.7)
(763.1)
13,296
9,420
(4,239)
(3,945)
(3,074)
33.8%
13Income tax expense
(1)
(0.1)
(0.3)
(0.7)
(2.6)
(1,083)
(1,213)
(772)
(46)
(54)
55%
14Net Income
(216.2)
(255.9)
(384.7)
(514)
(747.1)
12,202
8,362
(4,714)
(3,561)
(2,822)
33%
15% Margin
(199.5)%
(124.3)%
(284.8)%
(853.7)%
(93)%
68.8%
44.3%
(68.8)%
(111.3)%
(145.2)%
(176.8)% A
16Shares Outstanding
64.1
376
328.8
330.8
381.3
431
416
382
384
389
22.2%
17EPS Basic
(3.8)
(0.7)
(1.2)
(1.5)
(2)
30.3
21.3
(12.3)
(9.3)
(7.3)
7.5%
18EPS Diluted
(3.8)
(0.7)
(1.2)
(1.5)
(2)
28.3
20.1
(12.3)
(9.3)
(7.3)
7.5%
19EBITDA
(208.7)
(235.3)
(412)
(477.1)
(703.4)
13,535
9,952
(3,283)
(3,394)
(2,553)
32.1%
% Margin
(192.5)%
(114.3)%
(305.1)%
(792.4)%
(87.6)%
76.3%
52.7%
(47.9)%
(106.1)%
(131.3)%
(164.8)% A
20Net Interest Income (expense)
11.3
15.1
23.9
31.9
14.8
-
171
383
401
304
44.2%
21Net Debt / EBITDA
0.2
0.5
1.5
0.2
3.4
(0.4)
(0.2)
0.5
0.3
0.3
0.6 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
50.1
134.9
658.4
235.9
2,624
6,848
3,205
2,907
1,927
2,595
55.1%
23Short-term investments
1,008
621.2
863.1
867.1
1,984
3,879
6,697
5,697
5,098
3,204
13.7%
24Accounts receivable
18
18.4
30.6
16.3
1,408
3,323
1,685
1,081
592
284
35.9%
25Other current assets
11.1
8.8
11
9.5
235
580
895
438
365
308
44.7%
26Inventory
-
-
-
-
47
1,441
949
202
117
153
26.6%
27Total Current Assets
1,087
783.2
1,563
1,129
6,298
16,071
13,431
10,325
8,099
6,544
22.1%
Non-Current Assets
28Net property, plant & equipment
81.2
139
212
287.9
387
1,383
2,139
2,658
2,955
2,853
48.5%
29Long-term investments
236.6
145.9
173
160
639
6,843
8,360
4,743
2,508
2,342
29%
30Other non-current assets
12.2
16.4
14.2
12.7
13
372
1,928
700
580
599
54.1%
31Total Non-Current Assets
330
301.3
399.1
460.6
1,039
8,598
12,427
8,101
6,043
5,794
37.5%
Total Assets
1,417
1,085
1,962
1,589
7,337
24,669
25,858
18,426
14,142
12,338
27.2%
LIABILITIES
Current Liabilities
32Accounts payable
28.2
20.7
31.2
7.1
18
302
487
520
405
317
30.9%
33Short-term debt
-
-
-
-
30
211
196
25
37
-
5.4%
34Other current liabilities
134.6
170.7
191.6
136
4,341
8,615
4,240
2,470
1,764
1,670
32.3%
35Total Current Liabilities
162.8
191.5
222.8
143.1
4,389
9,128
4,923
3,015
2,206
1,987
32.1%
Non-Current Liabilities
36Long-term debt
12.5
15.7
33.5
132.4
207
705
1,004
1,218
710
1,916
74.9%
37Other non-current liabilities
400
252
175.6
139.1
180
691
808
339
325
(215)
-
38Total Non-Current Liabilities
412.5
267.7
209.1
271.5
387
1,396
1,812
1,557
1,035
1,701
17.1%
39Total Liabilities
575.3
459.2
431.9
414.6
4,776
10,524
6,735
4,572
3,241
3,688
22.9%
SHAREHOLDERS` EQUITY
40Common stock
-
-
-
-
-
-
-
-
-
-
78.3%
41Retained earnings / (deficit)
(365.7)
(621.9)
(1,007)
(1,497)
(2,244)
9,958
18,320
13,606
10,045
7,223
-
42Accumulated other comprehensive income / (loss)
(0.4)
(1.2)
(1.3)
1.8
3
(24)
(370)
(123)
(10)
45
-
43Noncontrolling interests
-
-
-
-
-
-
-
-
-
-
-
44Total shareholders' equity
841.9
625.3
1,530
1,175
2,561
14,145
19,123
13,854
10,901
8,650
29.5%
45Total Liabilities and shareholders' Equity
1,417
1,085
1,962
1,589
7,337
24,669
25,858
18,426
14,142
12,338
27.2%
46Total Debt
12.5
15.7
33.5
132.4
237
916
1,200
1,243
747
1,916
74.9%
47Net Debt
(37.6)
(119.2)
(624.9)
(103.5)
(2,387)
(5,932)
(2,005)
(1,664)
(1,180)
(679)
37.9%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
(216.2)
(255.9)
(384.7)
(514)
(747.1)
12,202
8,362
(4,714)
(3,561)
(2,822)
33%
49Depreciation & amortization
15.1
20.5
24.9
31
93
232
348
621
189
215
34.3%
50Share-based compensation expense
39.4
40.1
72.6
81.1
93
142
226
305
429
483
32.1%
51Changes in working capital and other assets
228.5
(136.2)
(43.6)
(57.1)
2,588
1,044
(3,955)
670
(61)
251
1.1%
52Net cash flows from operating activities
66.7
(331.5)
(330.9)
(459)
2,027
13,620
4,981
(3,118)
(3,004)
(1,873)
-
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(33.1)
(58.4)
(105.8)
(31.6)
(67.4)
(284)
(400)
(707)
(1,051)
(192)
21.6%
54Purchases of investments / marketable securities
(1,416)
(727.2)
(1,228)
(1,145)
(2,956)
(12,652)
(11,435)
(3,783)
(6,529)
(5,768)
16.9%
55Proceeds from maturities of marketable securities
808.9
1,203
960.4
1,162
1,352
4,443
6,699
8,781
9,529
7,916
28.9%
56Other investing activities
(8.9)
(1.3)
0.6
-
-
(30)
(40)
(85)
-
(10)
1.3%
57Net cash flows from investing activities
(648.6)
416.1
(372.5)
(14.9)
(1,672)
(8,523)
(5,176)
4,206
1,949
1,946
-
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
-
0.2
1,217
50.2
2,039
(733)
(3,264)
(1,107)
66
35
89.3%
59Dividends paid, net
(0.6)
(1.5)
-
-
-
-
-
-
-
-
134.3%
60Debt issuance (repayments), net
-
1.4
9.5
1
(6)
(140)
(184)
(270)
(10)
539
109.7%
61Other financing activities
473.5
-
-
-
0.2
-
-
-
-
19
(30)%
62Net cash flows from financing activities
472.9
0.2
1,227
51.1
2,033
(873)
(3,448)
(1,377)
56
593
2.6%
63Increase (decrease) in cash and cash equivalents
(109)
84.8
523.5
(422.8)
2,388
4,224
(3,643)
(289)
(999)
668
-
64Cash and equivalents, ending balance
50.1
134.9
658.4
247.7
2,636
6,860
3,217
2,928
1,929
2,597
55.1%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
33.6
(389.9)
(436.6)
(490.5)
1,960
13,336
4,581
(3,825)
(4,055)
(2,065)
-

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
20252024202320222021202020192018

Moderna (MRNA) financial statements and performance

Explore Moderna (MRNA) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.